Qing Yang Shi

Researchers are evaluating the safety and effectiveness of Qishen Yiqi Dripping Pills for treating adults aged 18 to 80 with chronic heart failure characterized by reduced ejection fraction due to coronary heart disease, specifically involving Qi deficiency with blood stasis syndrome. This phase 3 trial aims to compare these pills with a placebo to understand their impact on this condition. Participants will receive either Qishen Yiqi Dripping Pills or a matching placebo, both taken orally as 2 bags three times a day, half an hour after meals, over a 12-week period. The study uses a randomized, parallel design with quadruple masking to assess the effects. During the 12 weeks, participants will be monitored through various assessments including the 6-minute walk test, echocardiographic measurements, heart failure symptom evaluations, laboratory tests for biomarkers like NT-proBNP, and quality of life questionnaires. Researchers will track changes from baseline at weeks 4, 8, and 12 to evaluate exercise capacity, symptom improvement, heart function, and safety outcomes throughout the study.